Provider Briefing: Esterified Estrogens/Methyltestosterone Availability in 2026

If your patients are reporting difficulty filling Esterified Estrogens/Methyltestosterone prescriptions, this isn't an isolated problem. This combination estrogen-androgen therapy — marketed generically as EEMT and previously under brand names Estratest, Covaryx, Essian, and Menogen — has experienced persistent availability challenges that directly affect patient care.

This briefing covers the current supply landscape, prescribing implications, cost considerations, and practical tools to help you manage patients who depend on this medication.

Timeline: How We Got Here

Understanding the supply trajectory helps contextualize the current situation:

• 2000s-2010s: Multiple brand-name products (Estratest, Estratest H.S., Covaryx, Covaryx HS, Essian, Menogen, Syntest) were available from various manufacturers, providing adequate market supply.
• 2010s-2020: Progressive brand discontinuations. Estratest — the most recognized brand — was discontinued. Covaryx and other brands followed. Market consolidation to a small number of generic manufacturers.
• 2020-2024: The FDA issued a final rule on exempt anabolic steroid products (June 2020), clarifying the Schedule III status of some formulations. Intermittent availability issues reported by pharmacists and patients.
• 2025-2026: Generic EEMT and EEMT HS remain the primary available products. Supply is inconsistent — not a formal FDA-listed shortage, but functionally limited in many markets.

Prescribing Implications

Regulatory Considerations

There are several unique aspects to Esterified Estrogens/Methyltestosterone that affect prescribing:

• Schedule III controlled substance: Methyltestosterone is an anabolic steroid classified under DEA Schedule III. Prescriptions require appropriate DEA registration and are subject to controlled substance prescribing requirements including refill limitations (up to 5 refills within 6 months).
• Pre-NDA marketing status: This product has not been approved through the modern FDA New Drug Application pathway. It is marketed under older regulatory provisions and carries the notation that "this product has not been reviewed by the FDA for safety and effectiveness." This may be relevant to informed consent discussions.
• Boxed warnings: The label carries the standard estrogen boxed warnings regarding endometrial cancer risk, cardiovascular disease, and the WHI/WHIMS findings. These apply to all estrogen-containing hormone therapies.

Clinical Positioning

Esterified Estrogens/Methyltestosterone is indicated for moderate to severe vasomotor symptoms in postmenopausal women who have not responded adequately to estrogen-alone therapy. The addition of methyltestosterone is intended for patients in whom estrogen monotherapy provided insufficient symptom relief.

Key clinical considerations:

• Treatment should be at the lowest effective dose for the shortest duration consistent with treatment goals
• Standard dosing is cyclical: 3 weeks on, 1 week off
• Monitor for virilizing effects (acne, hirsutism, voice deepening, male-pattern alopecia) — particularly with prolonged use
• Regular monitoring should include liver function tests, lipid panels, mammography, and endometrial surveillance when clinically indicated
• Drug interactions to monitor: warfarin (methyltestosterone potentiates anticoagulation), insulin/oral hypoglycemics, corticosteroids, and CYP3A4 inducers/inhibitors

For detailed interaction guidance, see our clinical reference on Esterified Estrogens/Methyltestosterone drug interactions.

Current Availability Picture

As of early 2026:

• FDA Drug Shortage Database: Not currently listed
• Market reality: Inconsistent availability at retail pharmacies; many chain locations do not routinely stock this product
• Available formulations: Generic EEMT (1.25 mg/2.5 mg) and EEMT HS (0.625 mg/1.25 mg) — oral tablets only
• Manufacturers: Limited to a small number of generic producers
• Compounding: Compounding pharmacies can prepare equivalent formulations when commercial products are unavailable

Cost and Access Considerations

Cost can be a significant barrier for patients, particularly those without insurance coverage:

• Average retail price: $140-$150 for 30 tablets without insurance
• With discount coupons (GoodRx, SingleCare): $34-$39 per month
• Insurance coverage: Most Medicare Part D and commercial plans cover the generic. Typical tier placement is Tier 2 or Tier 3. Some plans require prior authorization or step therapy (trial of estrogen-alone therapy first).
• No active manufacturer savings programs currently exist for this product

Providers should proactively discuss cost with patients and recommend savings strategies including discount cards and patient assistance programs through NeedyMeds and RxAssist.

Tools and Resources for Your Practice

Real-Time Pharmacy Availability

Medfinder for Providers enables you and your staff to check which pharmacies near your patients currently have Esterified Estrogens/Methyltestosterone in stock. This can be integrated into your prescribing workflow to avoid sending prescriptions to pharmacies that don't carry the medication.

Alternative Prescribing Options

When Esterified Estrogens/Methyltestosterone is unavailable, consider these alternatives based on clinical presentation:

• Vasomotor symptoms responsive to estrogen alone: Estradiol (oral, transdermal, or topical) ± progestogen for endometrial protection
• Estrogen-progestin combination needed: Prempro, Premphase, or Bijuva (bioidentical)
• Testosterone component specifically needed: Compounded estrogen/testosterone preparation, or estrogen therapy plus off-label testosterone (topical or pellet)
• Patient prefers bioidentical: Bijuva (estradiol/progesterone) or compounded bioidentical hormones

For a patient-friendly comparison, see our alternatives guide.

Compounding Considerations

For patients who specifically require the estrogen-testosterone combination, a compounding prescription may be appropriate. Ensure you work with a PCAB-accredited or state-licensed compounding pharmacy and specify:

• Exact doses of esterified estrogens and methyltestosterone (or bioidentical testosterone)
• Dosage form (typically oral capsule)
• Quantity and refills
• Cyclical dosing instructions if applicable

Looking Ahead

The long-term outlook for Esterified Estrogens/Methyltestosterone availability remains uncertain. The product's pre-NDA regulatory status, the controlled substance classification of methyltestosterone, and the relatively small patient population create structural barriers to expanded manufacturing.

Providers should consider:

• Having contingency plans for patients on this medication
• Discussing alternative therapies proactively rather than reactively when patients can't fill prescriptions
• Building relationships with compounding pharmacies that can serve as a backup source
• Using tools like Medfinder for Providers to streamline the pharmacy search process

Final Thoughts

While Esterified Estrogens/Methyltestosterone isn't in a formal shortage, the practical reality is that many patients face difficulty accessing this medication in 2026. As prescribers, we can mitigate patient impact by staying informed about the supply landscape, maintaining familiarity with alternatives, and leveraging tools that improve prescribing efficiency.

For additional provider resources, visit medfinder.com/providers. For a patient-facing perspective on this issue, see our patient shortage update.